Clinical Trial Categories
  • Age & Physical Activity (1)
  • Alzheimer's Disease (7)
  • Arthritis (3)
  • Asthma (1)
  • Cancer - Bladder (1)
  • Cancer - Brain & CNS (16)
  • Cancer - Breast (8)
  • Cancer - Colon/Colorectal (2)
  • Cancer - Digestive System (2)
  • Cancer - Female Reproductive (8)
  • Cancer - Gastric (1)
  • Cancer - Kidney (2)
  • Cancer - Leukemia (6)
  • Cancer - Liver (1)
  • Cancer - Lung (3)
  • Cancer - Lymphoma (27)
  • Cancer - Melanoma (15)
  • Cancer - Mesothelioma (2)
  • Cancer - Myeloma (10)
  • Cancer - Other (5)
  • Cancer - Ovarian (2)
  • Cancer - Pancreas (2)
  • Cancer - Peritoneal (5)
  • Cancer - Prostate (12)
  • Cancer - Sarcoma (1)
  • Cancer - Stomach (1)
  • Cancer - Testicular (1)
  • Cancer - Tissue (6)
  • Crohn's Disease (3)
  • Dermatitis (2)
  • Dermatomyositis (1)
  • Healthy (6)
  • Hepatitis C (2)
  • HIV (4)
  • HPV (1)
  • Hypercholesterolemia (1)
  • Immune Disease - Autoimmune (9)
  • Immune Disease - Primary (2)
  • Immune Disease - Secondary (6)
  • Infectious Disease (2)
  • Inflammatory Disease (3)
  • Kidney Transplant (1)
  • Liver Disease (2)
  • Lupus Erythematosus (3)
  • Multiple Sclerosis (3)
  • Neurodegenerative (1)
  • OX40 (1)
  • Parkinson's Disease (1)
  • Pediatric (3)
  • Transplant (2)

KLH in Clinical Trials

Clinical trials involving KLH. Details such as study status, design and investigators are available by link to outside sites.

Clinical trial links are intended for informational purposes only, and are not solicitations for any study nor provided for the purposes of giving medical advice. See Terms of Use for this site.

(in order by date)

Entries in Adjuvant QS-21 (16)

Monday
Nov222010

NCT01248273

Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Conditions: Fallopian Tubes, Ovarian Cancer, Peritoneal Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I

Wednesday
Apr082009

NCT00878410

Immunoglobulin and QS-21 in Patients With Follicular Lymphomas 

Conditions: Lymphoma
Sponsors: National Cancer Institute (NCI)
Phase I

Friday
Jun132008

NCT00698711

Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I

Tuesday
Jan082008

NCT00597272

Thursday
May032007

NCT00470574

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

Conditions: Breast Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center. National Cancer Institute (NCI)
Phase n/a

Monday
May132002

NCT00036933

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center 
Phase II

Thursday
Feb142002

NCT00030823

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

Conditions: Breast Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I

Sunday
May062001

NCT00016120

Vaccine Therapy Plus Biological Therapy in Treating Patients With Relapsed Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase II

Wednesday
Jul052000

NCT00006041

Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I

Tuesday
May022000

NCT00005632

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I

Page 1 2 Next 10 Entries »